Lantern Pharma Inc. (NASDAQ:LTRN – Get Rating) – Stock analysts at HC Wainwright issued their Q2 2023 earnings per share estimates for shares of Lantern Pharma in a research note issued on Thursday, May 18th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Lantern Pharma’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Lantern Pharma’s Q4 2023 earnings at ($0.47) EPS, FY2023 earnings at ($1.65) EPS, FY2024 earnings at ($2.32) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($0.87) EPS.
Lantern Pharma (NASDAQ:LTRN – Get Rating) last announced its earnings results on Monday, March 20th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.18. During the same period last year, the company earned ($0.31) EPS.
Lantern Pharma Trading Up 6.4 %
LTRN stock opened at $5.00 on Monday. The stock has a 50-day moving average price of $4.88 and a 200-day moving average price of $5.18. Lantern Pharma has a 1-year low of $4.05 and a 1-year high of $6.59. The firm has a market cap of $54.30 million, a PE ratio of -3.88 and a beta of 0.65.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in shares of Lantern Pharma by 52.7% in the 1st quarter. JPMorgan Chase & Co. now owns 8,018 shares of the company’s stock worth $57,000 after acquiring an additional 2,768 shares in the last quarter. Lynwood Capital Management Inc. bought a new stake in Lantern Pharma in the 4th quarter valued at about $73,000. Renaissance Technologies LLC bought a new stake in Lantern Pharma in the 1st quarter valued at about $77,000. UBS Group AG increased its position in Lantern Pharma by 23.7% in the 4th quarter. UBS Group AG now owns 14,841 shares of the company’s stock valued at $90,000 after buying an additional 2,841 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Lantern Pharma in the 4th quarter valued at about $91,000. 21.63% of the stock is owned by institutional investors.
About Lantern Pharma
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.
- Get a free copy of the StockNews.com research report on Lantern Pharma (LTRN)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.